|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
|
1R01CA231291-01
|
$533,211
|
WELLSTEIN, ANTON
|
GEORGETOWN UNIVERSITY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
5R01CA205965-02
|
$640,839
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
|
1R01CA219871-01A1
|
$451,326
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
|
1R01CA231295-01
|
$481,288
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
1/2 Langston University- UNTHSC Partnership for Cancer Research and Education
|
1P20CA233391-01
|
$210,731
|
QUINN, BYRON
|
LANGSTON UNIVERSITY
|
|
1/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202924-03
|
$190,920
|
WILLIAMS, KEVIN
|
NORTH CAROLINA CENTRAL UNIVERSITY
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221697-01S1
|
$47,364
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221697-02S1
|
$142,991
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
5P20CA221697-02
|
$310,904
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233396-01
|
$1,008,781
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
3P20CA202925-03S1
|
$104,165
|
PATIERNO, STEVEN
|
DUKE UNIVERSITY
|
|
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202925-03
|
$278,348
|
PATIERNO, STEVEN
|
DUKE UNIVERSITY
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221696-02S1
|
$122,850
|
MCNEILL, LORNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
2/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
5P20CA221696-02
|
$222,707
|
MCNEILL, LORNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233444-01
|
$1,054,795
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233465-01
|
$1,141,251
|
CARPTEN, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-13
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D Models of Immunotherapy
|
5U01CA214369-02
|
$729,562
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
3D Prostate Histochemometry to Predict Disease Recurrence
|
5R01CA197516-03
|
$400,610
|
BHARGAVA, ROHIT
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 02060
|
$79,723
|
Rothman, Nat
|
DCEG (NCI)
|
|
A comparison of interventions to teach patients skin self-examination
|
5R01CA154908-08
|
$724,343
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
|
1R01CA222871-01
|
$373,547
|
FISHER, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5U01CA164974-08
|
$3,131,894
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
|
1R21CA226303-01
|
$176,175
|
HE, TONG-CHUAN
|
UNIVERSITY OF CHICAGO
|
|
A germline variant that predicts and modulates the response of melanoma to immunotherapy
|
5R21CA209309-02
|
$237,724
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-10
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A high-throughput platform for neo-antigen based cancer immunotherapy
|
1R43CA233120-01
|
$299,917
|
XIAO, JUN
|
IMMUDX, LLC
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$154,883
|
Kelly Siebenlist, Kathleen
|
CCR (NCI)
|
|
A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions
|
1R44CA228897-01
|
$299,244
|
HACHEY, DAVID
|
FRONTIER DIAGNOSTICS, LLC
|
|
A Multilevel Intervention to Increase the Participation of African Americans in Prostate Cancer Clinical Trials
|
5R01CA200718-03
|
$665,635
|
EGGLY, SUSAN
|
WAYNE STATE UNIVERSITY
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use
|
7R01CA207645-03
|
$575,548
|
OSBORNE, JOSEPH
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-03
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|